Eli Lilly and Company will supply active pharmaceutical ingredient (API) for human insulin at a reduced price to International Agencies (Bangladesh) to increase patient access and improve affordability for high-quality insulin for nearly one million people living with diabetes in Bangladesh by 2030. Lilly offers its human insulin API at reduced price to IABL to support insulin production in Bangladesh. This collaboration with IABL, will reduce barriers to access and ensure ongoing production and uninterrupted supply of insulin to help patients to lead healthier lives. This agreement has a remarkable potential to reach more patients with locally manufactured human insulins using Lilly's API and augment the company's Lilly 30X30 vision to transform communities and make life better for people around the world. According to the IDF Diabetes Atlas, 13.1 million people are living with diabetes in Bangladesh and it is expected to increase to about 22.3 million by 2045. Through the Lilly 30x30 initiative, Lilly is active in Bangladesh in additional capacities, including nonprofit collaborations to help improve health outcomes for children and adolescents living with chronic, non-communicable diseases (NCDs), and to provide high-quality diabetes care and treatment for children with type 1 diabetes.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!